Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14659014 | 0.83 | FFAR1 (0.42) | HCRTR2S1PR1S1PR3TACR3PDE10A | |
| SCHEMBL1003112 | 0.79 | MAPT (0.36) | MAPTPKMMEN1KMT2APDE10A | |
| SCHEMBL9820889 | 0.73 | MAPT (0.44) | MAPTPKMMEN1KMT2A | |
| SCHEMBL19182180 | 0.73 | MAPT (0.53) | MAPTPKMMEN1KMT2A | |
| SCHEMBL2681954 | 0.73 | MAPT (0.40) | MAPTPKMMEN1KMT2A | |
| SCHEMBL15235893 | 0.73 | ALDH1A1 (0.55) | MAPTPKMMEN1KMT2A | |
| SCHEMBL6082774 | 0.73 | ALDH1A1 (0.55) | MAPTPKMMEN1KMT2A | |
| SCHEMBL15977387 | 0.73 | ALDH1A1 (0.55) | MAPTPKMMEN1KMT2A | |
| SCHEMBL10692330 | 0.72 | MAPT (0.46) | MAPTPKM | |
| SCHEMBL433974 | 0.71 | MAPT (0.47) | MAPTPKMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144119-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME LLC | 2011-06-16 | — | — | US | disclosed |
| US-20110021531-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144119-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | FAAH, FAAH2, ALOX5 | MAPT 1377/4885PKM 281/4885HCRTR2 4/4885 |
| US-20110021531-A1 | OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | FAAH, FAAH2, ALOX5 | MAPT 1378/4885PKM 343/4885HCRTR2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.